Twist Bioscience targets $442M-$447M FY2026 revenue while staying on track for Q4 FY2026 adjusted EBITDA breakeven (NASDAQ:TWST)
Twist BioscienceTwist Bioscience(US:TWST) Seeking Alpha·2026-05-05 01:54

新闻内容技术访问问题 - 新闻内容因浏览器设置问题无法加载 用户需启用Javascript和cookies或禁用广告拦截器以正常访问 [1]

Twist Bioscience targets $442M-$447M FY2026 revenue while staying on track for Q4 FY2026 adjusted EBITDA breakeven (NASDAQ:TWST) - Reportify